Report cover image

Prinzmetal Angina Therapeutics Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Publisher Credence Research Inc
Published Feb 04, 2025
Length 190 Pages
SKU # CRRE20019805

Description

Market Overview
The Prinzmetal Angina Therapeutics Market is projected to grow from USD 10,715 million in 2024 to USD 16,258.05 million by 2032, registering a compound annual growth rate (CAGR) of 5.35% over the forecast period (2024–2032).

Market growth is fueled by the rising incidence of Prinzmetal Angina, particularly among the aging population, coupled with increasing awareness and advancements in cardiovascular diagnostics. The expanded use of therapies such as calcium channel blockers and nitrates for treating coronary artery spasms continues to enhance therapeutic outcomes. Additionally, the growing burden of risk factors including hypertension, diabetes, and smoking is further elevating the demand for targeted angina treatments. Investments in R&D and the regulatory approval of novel therapies are further supporting the market’s trajectory.

Market Drivers

Advancements in Therapeutic Approaches
Innovations in treatment options, including combination therapies and advancements in calcium channel blockers (e.g., amlodipine, nifedipine) and nitrates (e.g., nitroglycerin), are enhancing clinical outcomes for Prinzmetal Angina patients. The shift toward personalized medicine and targeted therapies is leading to more effective patient management strategies, promoting stronger demand for specialized therapeutic interventions. These improvements are instrumental in increasing the acceptance and utilization of advanced treatments across healthcare systems globally.

Market Challenges

Limited Awareness and High Treatment Costs
Despite advancements, limited awareness among healthcare providers remains a key challenge. Due to its rare and episodic nature, Prinzmetal Angina is frequently misdiagnosed or overlooked, delaying appropriate care. This lack of awareness can lead to suboptimal treatment and underutilization of effective therapeutic options.

Additionally, the high cost of advanced and personalized treatments poses a significant barrier, particularly in low-income regions or for uninsured patients. Financial constraints and inconsistent healthcare access limit the widespread adoption of premium therapeutics, especially where healthcare infrastructure is underdeveloped.

Market Segmentation

By Drug Class:

Beta Blockers

Calcium Antagonists

Anti-Anginals

ACE Inhibitors

Anticoagulants

Antiplatelets

Nitrates

By Disease Type:

Variant and Microvascular Angina

Unstable Angina

Stable/Chronic Angina

By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

By Region:

North America: U.S., Canada, Mexico

Europe: Germany, France, U.K., Italy, Spain, Rest of Europe

Asia Pacific: China, Japan, India, South Korea, Southeast Asia, Rest of Asia Pacific

Latin America: Brazil, Argentina, Rest of Latin America

Middle East & Africa: GCC Countries, South Africa, Rest of MEA

Key Player Insights

Pfizer Inc.

Novartis AG

AstraZeneca Plc

Gilead Sciences Inc.

Sanofi S.A.

Eli Lilly

Amgen Inc.

GlaxoSmithKline Plc

Tasly Pharmaceuticals Inc.

XyloCor Therapeutics

Table of Contents

190 Pages
CHAPTER NO. 1 : INTRODUCTION
1.1.1. Report Description
Purpose of the Report
USP & Key Offerings
1.1.2. Key Benefits for Stakeholders
1.1.3. Target Audience
1.1.4. Report Scope
CHAPTER NO. 2 : EXECUTIVE SUMMARY
2.1. Prinzmetal Angina Therapeutics Market Snapshot
2.1.1. Prinzmetal Angina Therapeutics Market, 2018 - 2032 (USD Million)
CHAPTER NO. 3 : Prinzmetal Angina Therapeutics Market – INDUSTRY ANALYSIS
3.1. Introduction
3.2. Market Drivers
3.3. Market Restraints
3.4. Market Opportunities
3.5. Porter’s Five Forces Analysis
CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
4.1. Company Market Share Analysis – 2023
4.2. Prinzmetal Angina Therapeutics Market Company Revenue Market Share, 2023
4.3. Company Assessment Metrics, 2023
4.4. Start-ups / SMEs Assessment Metrics, 2023
4.5. Strategic Developments
4.6. Key Players Product Matrix
CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
CHAPTER NO. 6 : Prinzmetal Angina Therapeutics Market – BY By Drug Class: ANALYSIS
CHAPTER NO. 7 : Prinzmetal Angina Therapeutics Market – BY By Disease Type: ANALYSIS
CHAPTER NO. 8 : Prinzmetal Angina Therapeutics Market – BY By Distribution Channel: ANALYSIS
CHAPTER NO. 9 : Prinzmetal Angina Therapeutics Market – BY By Region: ANALYSIS
CHAPTER NO. 10 : COMPANY PROFILES
10.1. Pfizer Inc.
Company Overview
Product Portfolio
Swot Analysis
Business Strategy
Financial Overview
10.2. Novartis AG
10.3. AstraZeneca Plc
10.4. Gilead Sciences Inc.
10.5. Sanofi S.A.
10.6. Eli Lilly
10.7. Amgen Inc.
10.8. GlaxoSmithKline Plc
10.9. Tasly Pharmaceuticals Inc.
10.10. XyloCor Therapeutics

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us